key: cord-1047239-k9jgdp66
authors: Pecora, Nicole D.; Zand, Martin S.
title: Measuring the Serological Response to SARS-CoV-2: Methods and Meaning
date: 2020-08-08
journal: Clin Lab Med
DOI: 10.1016/j.cll.2020.08.014
sha: 53085c7a49c5340acdb259f5d197541e013481e1
doc_id: 1047239
cord_uid: k9jgdp66

The entire spectrum of diagnostic testing, from reagent supply to test performance, has been a major focus during the COVID-19 pandemic. The hope for serological testing is that it would provide both epidemiological information about seroprevalence as well as individual information about previous infection. This is particularly helpful for high risk individuals who may be outside of the viral shedding window, such as children with suspected MIS-C. It is not yet understood whether serological testing can be interpreted in terms of protective immunity. These concerns must be addressed using highly sensitive and specific tests.

as individual information about previous infection. This is particularly helpful for high risk individuals who may be outside of the viral shedding window, such as children with suspected MIS-C. It is not yet understood whether serological testing can be interpreted in terms of protective immunity. These concerns must be addressed using highly sensitive and specific tests.

The COVID-19 pandemic began in December 2019 with several cases of a pneumonia of unknown etiology in Wuhan, China 1 . The causative agent was quickly identified using molecular techniques as the Betacoronavirus SARS-CoV-2 2 . This discovery was followed by a global effort to develop accurate molecular diagnostics at tremendous scale and pace in order to diagnose acute infection and contain spread of the virus. Questions about serological testing followed soon after.

Early in the pandemic, lack of regulatory restrictions on serological testing led to a wave of over 40 antibody tests to detect IgG and/or IgM binding to SARS-CoV-2 spike and nucleocapsid proteins [3] [4] [5] [6] [7] [8] [9] . Many of these tests were poorly characterized, which caused concern about the quality of serological data. A number of discussions about "immunity passports" caused further concern about the use of serological data 10 . In response, the US Food and Drug Administration moved to tighten regulation of new commercial serological tests; over 30 have been subsequently withdrawn from distribution 11 . These events have highlighted the importance of rigorous testing evaluation and scope of use. At the same time, tremendous effort has been focused on understanding the immune response to SARS-COV-2, both from data coming out of the hardest hit regions and from previous knowledge gleaned from the study of SARS-CoV-1, MERS, and circulating human coronaviruses (HCoVs). This knowledge has helped to refine the questions of: Who to test for antibodies to SARS-CoV-2? and for what purpose should they be tested 12 ?

Here we review the basis of antibody-mediated immunity to SARS-CoV-2 and other coronaviruses, with a focus on kinetics and correlates of protection. We then discuss currently available testing options for SARS-CoV-2 antibodies in the context of the rapidly evolving knowledge of disease immunopathogenesis, and how testing may be used to inform a diverse and complicated set of questions.

J o u r n a l P r e -p r o o f SARS-CoV-2 is a member of the family Coronaviridae, which consists of 2 genera that infect mammals: Alpha-and Betacoronaviridae 13 . Strains which are relevant to human infections include the four circulating seasonal coronaviruses: 229E and NL63 (both Alphacoronaviridae), and OC43, HKU1, MERS-CoV, and SARS-CoV-1 (all Betacoronaviridae) 13 . All of the coronaviruses are enveloped RNA viruses with genomes in the range of 30 kilobases. (Figure 1 ). The first portion of the genome consists of open reading frames (ORF) 1a and 1b, encoding the replicase-transcriptase polyprotein (pp1ab), followed by 4 structural proteins: spike (S), nucleocapsid (NP), envelope (E), and membrane (M). Studies on SARS-CoV-1 indicated that the structural nucleocapsid (NP) and spike (S) proteins are the dominant antigens for host immune responses to SARS-CoV-2 14, 15 .

The mature spike (S) protein is a ~180 kDa glycosylated, homotrimer that protrudes from the viral surface, giving the characteristic halo appearance for which coronaviruses are named 16 . The extracellular region is organized into the S1 and S2 domains. S1

comprises the outermost region, contains the receptor binding domain (RBD) for the target human ACE2 receptor, and initiates host cell entry [17] [18] [19] [20] . Studies of SARS-CoV-1 demonstrate that receptor binding and proteolytic cleavage at the S1/S2 junction triggers a conformational change in S2 which mediates entry via the membrane fusion peptide sequence 21 . The spike protein is moderately conserved among members of the Betacoronaviridae, particularly the S2 region proximal to the viral surface ( Figure 2 ) 22 . The S1

region, including the RBD, is less conserved and of great interest as a target for immunoassays due to its prime role in interaction with the human host 22 . Several studies have demonstrated that anti-spike antibodies can neutralize virus in cell culture, and efforts towards vaccine development are heavily focused on this protein 16, 17, [23] [24] [25] .

Functional and biochemical studies on the ~50-kDa SARS-CoV-1 and -2 nucleocapsid proteins demonstrate roles in replication, transcription, and packaging of the genome 26, 27 (Figure 3 ). The high abundance and antigenicity of nucleocapsid protein (NP) have made it a focus of both diagnostic and vaccine work for SARS-CoV-1 as well as SARS-CoV-2 [28] [29] [30] . NP sequences demonstrate 99% identity with related bat coronaviruses (RaTG13) and ~ 90% identity with SARS-CoV-1 31 .

These sequence homologies have implications for antibody testing. By sequence analysis, the normal circulating CoV strain OC43 has moderate homology with SARS-CoV-2 in both the nucleocapsid and spike proteins ( Figure 4 ). Sequence similarities can translate into cross-strain antibody binding, decreasing test specificity when used to determine infection prevalence. In contrast, increased specificity may occur from strain differences on surface sequences that are likely targets of antibody mediated responses. There are conflicting reports regarding the disease course kinetics of anti-NP and -S antibody detection, and thus the relative sensitivity of serologic tests. Some reports have shown detection of anti-NP slightly earlier than anti-S antibodies, while others have shown the contrary, possibly due to differences in assay format 36, 37 . Similarly, human SARS-CoV-1 anti-NP antibodies were detectable by serological assays slightly earlier than anti-S Ig 38, 39 . Additional studies have suggested that assays using more restricted epitopes, namely S1 or RBD, may be more specific than those using the full spike protein [32] [33] [34] 36, 40 . Importantly, while antibody responses may be detectable in the first week after symptom onset, a full 2-3 weeks is required for a robust response 9, 36, 41 .

Over the course of infection, IgM and IgA appeared earliest, often within 5 days of symptom onset, though IgG appeared in close succession [32] [33] [34] 36, 40 .

With respect to the kinetics of viral RNA (the viral shedding window), antibodies appear to become detectable as the viral load diminishes [33] [34] [35] . However, patients with both mild and severe clinical presentations may generate a detectable antibody response before viral clearance 34, 35, 42 . In contrast, there have been reports that asymptomatic (RT-PCR confirmed) individuals may demonstrate late onset or even no seroconversion 35 .

Much of the controversy surrounding SARS-CoV-2 serological testing has centered around fundamental aspects of test validation.

This was also true for SARS-CoV-1 43, 44 . SARS-CoV-2 antibody detection tests have used several platforms, including enzyme-linked immunosorbent assays (ELISA), chemiluminescent, lateral flow, and multiplex methods. All have been previously used to detect J o u r n a l P r e -p r o o f antibodies to other viral pathogens 45 . In general, these methods involve solid phase coupling of recombinant S-or NP-as fully trimerized (S-protein), monomeric (NP), or peptide fragments (S1-RBD, linear peptide fragments). The solid phase coupled proteins are incubated with serum to allow immunoglobulin binding, which is detected by a secondary anti-IgG/IgA/IgM reagent. Assay readouts include serum dilution titers, colorimetic absorbance, changes in surface reflectivity, or fluorescence intensity.

Assay validation requires a set of known positive and negative serum samples. Archived samples from the pre-COVID-19 era (e.g.

pre-2020) can be used for a negative "gold standard". There is particular interest in determining the false positive rate as the presence of antibodies will be interpreted as proof of prior infection. Across multiple studies, specificity of ELISA-format assays has been reported to be between 95- For any clinical assay, the trade-off between specificity and sensitivity is a key factor in how it will be ultimately used. For example, if a positive value is to be used as a surrogate marker for infection, with potential translation for immunity, minimizing the false positive rate is critical. In contrast, other considerations are a focus for a test that is used to monitor antibody kinetics after infection, in vaccine clinical trials, or to monitor convalescent plasma or monoclonal antibody therapy. Here, binary ("positive" or "negative") or titer (ranked categorical) test results are less useful than a continuous readout (i.e. absolute antibody concentrationng/ml), especially when performing statistical comparisons of vaccine efficacy in clinical trials 46 or determining who should donate convalescent plasma. Identifying antibody subsets poses another challenge for test validation. The acceptable threshold for anti-S1/RBD antibodies may need to be different for convalescent plasma donor screening than for identifying post-infectious immunity. 

Some questions where antibody testing can provide clarity include seroprevalence and, on an individual level, whether a person has previously been infected with SARS-CoV-2 49 . This can be straightforward, such as when an individual had clinically suggestive symptoms weeks prior, but could or did not get a molecular test. Beyond simply assessing previous infection, there is considerable interest in interpreting serological test results as correlates of protection against future infection (Box 1). When using serological testing to answer such questions, it is important to consider: 1) the durability of the immune response, 2) the neutralization potential of antibodies, and 3) the translation of these findings into an assessment of functional in vivo immunity. Critically, we currently do not have data regarding the association between the presence and titers of anti-SARS-CoV-2-S or -NP antibodies and protection from re-infection.

The COVID-19 pandemic is still in its early stages, so there has not been the opportunity to assess the longevity of the antibody response, though small cohort studies show IgG antibodies are detectable for at least 6 weeks after symptom onset 35, 40 , while IgM is diminished within the first month post-infection 36, 40 . A recent study looking at IgG levels in asymptomatic vs. symptomatic individuals found that neutralizing titers were more likely to diminish in the early convalescent phase in those without a history of J o u r n a l P r e -p r o o f symptoms 50 . Furthermore, the same study demonstrated that 40.0% of asymptomatic individuals became seronegative in the convalescent phase versus only 12.9% of those who were symptomatic 50 . Previous reports indicate that individuals infected with SARS-CoV-1 have detectable IgG antibodies for at least 8-24 months after symptom onset, while IgM and IgA were markedly decreased [51] [52] [53] . In contrast, patients infected with the HCoV 229E have markedly diminished antibody levels one year post-infection 54 . Such results may complicate future interpretation of serologic test results, especially if SARS-CoV-2 infection becomes endemic and seasonal.

Plaque reduction neutralization tests (PRNTs) can assess whether infected patients mount a neutralizing antibody response to the virus. Serum or plasma from individuals infected with SARS-CoV-1 or SARS-CoV-2 has been shown in several studies to neutralize viral infectivity in vitro 24, 41, [55] [56] [57] . Several purified neutralizing antibodies have been characterized against epitopes of both SARS-CoV-1 and SARS-CoV-2, the majority of which are directed against the RBD of the spike protein 14, 16, [23] [24] [25] 58 . It remains to be seen how these findings can be translated in vivo to natural immunity or therapeutics.

Neutralizing antibodies are the basis for convalescent plasma therapy, which showed promise in treating patients with SARS-CoV-1, and is currently being tested for those with SARS-CoV-2. Monoclonal antibodies directed at the S1-RBD and other antigenic sites are also in development. Both classes of therapies pose opportunities and challenges for clinical serological testing. Convalescent plasma donors will need to be screened for high anti-SARS-CoV-2 protective titers, though we do not know which antibodies confer protection. Similarly, such tests may be used to monitor post-infusion antibody levels during convalescent plasma treatment, monoclonal antibody therapies, or post vaccination. Further complicating this issue is evidence from SARS-CoV-1 that antibody dependent enhancement (ADE) of infection may occur, where antibodies facilitate, rather than block, viral infection 59 . Current serological tests will do not distinguish between protective and ADE inducing antibodies. Such uses of a clinical test will need to be carefully monitored to assure that anti-SARS-CoV-2 antibody tests are suited to these goals.

Serological testing is an evolving and complex area of testing for COVID-19. Challenges include test validation and performance, usage, and interpretation across multiple contexts. As knowledge accumulates about the significance of differential and quantitative detection of viral antigens, it will be beneficial to have test platforms that can address questions going beyond a qualitative J o u r n a l P r e -p r o o f assessment of previous infection. Careful test validation and appropriate matching to the questions to be answered will help assure clinical and scientific research rigor and reproducibility. It is likely that the testing landscape for measuring the serological response to SARS-CoV-2 will evolve rapidly over the next several years. Furthermore, if it is determined that neutralizing antibodies do not confer protection (which we may know within 6-12 months) serologic testing for SARS-CoV-2 may be of purely epidemiological value and thus less likely to occur in clinical labs.

This work was supported by the National Institutes of Health Institute of Allergy, Immunology and Infectious Diseases grants R01 J o u r n a l P r e -p r o o f 

A Novel Coronavirus from Patients with Pneumonia in China

Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2

Diagnostic performance of COVID-19 serology assays

Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience

Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan

Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures

A serological assay to detect SARS-CoV-2 seroconversion in humans

COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges

What Tests Should No Longer Be Distributed for COVID-19?

The Promise and Peril of Antibody Testing for COVID-19

Origin and evolution of pathogenic coronaviruses

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes and infection

The trinity of COVID-19: immunity, inflammation and intervention

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural basis of receptor recognition by SARS-CoV-2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

The SARS-CoV nucleocapsid protein: a protein with multifarious activities. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases

Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochemical and biophysical research communications

Nucleocapsid protein as early diagnostic marker for SARS

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microbes and infection

Antibody Detection and Dynamic Characteristics in Patients with COVID-19

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease

Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerging microbes & infections

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2

Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients

Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clinical and diagnostic laboratory immunology

Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia

Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region

First external quality assurance of antibody diagnostic for SARS-new coronavirus

Serological assays for emerging coronaviruses: challenges and pitfalls

A Complex Dance: Measuring the Multidimensional Worlds of Influenza Virus Evolution and Anti-Influenza Immune Responses

Continuous Readout versus Titer-Based Assays of Influenza Vaccine Trials: Sensitivity, Specificity, and False Discovery Rates

Test performance evaluation of SARS-CoV-2 serological assays. medRxiv

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature medicine

Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus

Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome

Duration of antibody responses after severe acute respiratory syndrome

The time course of the immune response to experimental coronavirus infection of man

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection

A human monoclonal antibody blocking SARS-CoV-2 infection

The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development